Mechanistic insights into molecular targeted therapy and immunotherapy for lung cancer

Abstract

Lung cancer is a serious public health concern and a leading cause of cancer related deaths worldwide. The major drawback of conventional therapies such as chemotherapy, radiotherapy, and surgery is their limited efficacy and lack of tumor specificity. Of these treatment options, targeted therapy and immunotherapy are of best interest due to their potential to selectively target cancer cells and enhance immune responses. Targeted therapy can bind to molecular targets and inhibit pathways involved in cell growth, proliferation, and survival. In the case of lung cancer, targeting expressions of EGFR, KRAS, and BRAF are important as their overexpression makes up a significant portion of cancer cases. Targets in the MAPK, PI3K, and MYC pathway are also inhibited as each of these pathways promote cell proliferation and growth. Immunotherapy directly kills off cancerous cells by amplifying the behavior of immune cells. Immunotherapeutic targets include NK-cells, T-cells, and immune checkpoints. NK cells and T cells are involved in the elimination of cancer cells, while immune checkpoints regulate the immune system but may be exploited by cancerous cells. The advent of molecular targeted therapy and immunotherapy has significantly transformed lung cancer treatment, offering precision and efficacy in combating tumor resistance. Their integration in combination strategies holds great promise for improved clinical outcomes and represents a pivotal direction for future therapeutic advancements.